| 18.985 1.895 (11.09%) | 08-07 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 23.82 |
1-year : | 27.83 |
| Resists | First : | 20.39 |
Second : | 23.82 |
| Pivot price | 18.11 |
|||
| Supports | First : | 18.03 |
Second : | 16.56 |
| MAs | MA(5) : | 17.28 |
MA(20) : | 18.49  |
| MA(100) : | 20.65 |
MA(250) : | 27.55 |
|
| MACD | MACD : | -0.4 |
Signal : | -0.3 |
| %K %D | K(14,3) : | 37 |
D(3) : | 16.9 |
| RSI | RSI(14): 55.3 |
|||
| 52-week | High : | 48.45 | Low : | 16.36 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ AAPG ] has closed below upper band by 25.8%. Bollinger Bands are 23.3% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 17.16 - 17.24 | 17.24 - 17.32 |
| Low: | 16.57 - 16.66 | 16.66 - 16.75 |
| Close: | 16.93 - 17.09 | 17.09 - 17.23 |
Based in Suzhou, China, Ascentage Pharma Group International is a biotechnology firm primarily focused on clinical-stage development. The company is dedicated to discovering and advancing therapeutic solutions for a range of medical conditions, including various cancers, chronic hepatitis B virus (HBV) infections, and age-related ailments. A cornerstone of its product pipeline is HQP1351, a BCR-ABL inhibitor specifically designed to address BCR-ABL1 mutants, notably those carrying the T315I mutation. The company's portfolio also encompasses APG-2575, an orally administered, selective Bcl-2 inhibitor aimed at treating hematologic malignancies and solid tumors. Another key asset, APG-115, is an oral small molecule that intervenes in MDM2-p53 protein-protein interactions, showing potential for both solid and blood cancers. Further bolstering its oncology efforts is APG-1252, a small molecule therapy engineered to reactivate programmed cell death (apoptosis) by dually inhibiting Bcl-2 and Bcl-xL proteins, targeting diseases such as small-cell lung cancer, non-small cell lung cancer, neuroendocrine tumors, and non-Hodgkin's lymphoma. Beyond these, Ascentage is actively developing APG-1387, a small molecule apoptosis inhibitor designated for advanced solid tumors and chronic HBV. Its pipeline also features APG-2449, an oral inhibitor of FAK, ROS1, and ALK kinases; APG-5918, a selective, orally available embryonic ectoderm development inhibitor; APG-265, an MDM2 protein degrader; and UBX1967/1325, which are additional Bcl-2 inhibitors. In addition to its core pharmaceutical activities, the company engages in medical research, clinical trial operations, venture capital investments, and offers rental and technology promotion services. Ascentage Pharma also cultivates strategic partnerships with various biotechnology and pharmaceutical companies, alongside research institutions. The company was founded in 2009.
Fri, 07 Aug 2026
Ascentage Pharma Group International (AAPG) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Fri, 07 Aug 2026
Ascentage Pharma Group International (NASDAQ:AAPG) Shares Gap Up - Time to Buy? - MarketBeat
Thu, 06 Aug 2026
Ascentage Pharma Group International (6855.HK) stock price, news, quote and history - Yahoo Finance Australia
Thu, 06 Aug 2026
Ascentage Pharma Group International - ADR (AAPG) News, Articles, Events & Latest Updates - Stocktwits
Wed, 05 Aug 2026
Ascentage Pharma Group Internat (AAPG) Stock Price, News, Quote & History - Yahoo! Finance Canada
Wed, 05 Aug 2026
Ascentage Pharma to Report 2026 Six Month Interim Results and Provide Corporate Update on August 19, 2026 - globenewswire.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 93 (M) |
| Shares Float | 71 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 0 (%) |
| Shares Short | 20 (K) |
| Shares Short P.Month | 1 (K) |
| EPS | -2.06 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 2.1 |
| Profit Margin | -216.5 % |
| Operating Margin | -193.4 % |
| Return on Assets (ttm) | -23.1 % |
| Return on Equity (ttm) | -154.6 % |
| Qtrly Rev. Growth | 117 % |
| Gross Profit (p.s.) | 5.62 |
| Sales Per Share | 6.15 |
| EBITDA (p.s.) | -12.22 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -1,170 (M) |
| Levered Free Cash Flow | -943 (M) |
| PE Ratio | -9.22 |
| PEG Ratio | 0 |
| Price to Book value | 8.99 |
| Price to Sales | 3.08 |
| Price to Cash Flow | -1.52 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|